PROGRAMME of INDUSTRY SYMPOSIA2015.easd-industry.com/files/EASD15/downloads/industry/... · 2015-08-10 · Images shown are models used for illustrative purposes only SAGLB.DIA.15.06.0341

www.easd-industry.com

PROGRAMME of

INDUSTRY SYMPOSIA

STOCKHOLM14 September 201517 September 2015

on the occasion of the 51st Annual Meeting

of the European Association for the Study of Diabetes

INTERPLANmedia & service gmbh

2

CONTENT

Organised and funded by AstraZeneca

Individualised patient care in Type 2 diabetes:

Translating science to practiceSymposium on the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes

Making the right choice at the right time with our patients is key to ensuring their future wellbeing. But with the vast array of potential therapies now available, and the science behind diabetes management advancing rapidly, how can we ensure we are pursuing the optimal treatment approach with each individual?

In this symposium we will translate the science and bring our patients into focus through interactive talks, interviews, discussions and Q&A sessions with world-leading experts.

Join us to explore key questions in patient management, and share views and clinical experience with the aim of raising the standard of care for patients living with diabetes.

Join us and be part of the debate!

Monday 14 September 2015,10:30–16:30Heding Hall, Stockholmsmässan

What science can do

10:30–11:00 Welcome and introduction: why and when should we treat Type 2 diabetes? C Mathieu (Belgium), J Vora (UK)

11:00–11:30 Treatment decisions for our patients: what are the considerations? R Pratley (US)

11:30–11:55 Weight gain in the treatment of Type 2 diabetes: is it inevitable? J Wilding (UK)

11:55–12:20 The kidneys in Type 2 diabetes: challenges and opportunities? M Cooper (Australia)

12:20–12:45 Can we delay escalation to insulin therapy? T Vilsbøll (Denmark)

12:45–13:00 What steps should we take to stop progression of poor glucose control? Panel discussion led by C Mathieu (Belgium), J Vora (UK)

13:00–14:00 Lunch

14:00–14:10 Welcome back C Mathieu (Belgium), J Vora (UK)

14:10–14:40 Safety of novel therapies in Type 2 diabetes: what’s the latest? J Meier (Germany)

14:40–15:05 What is the physiological basis for combining therapies? J Holst (Denmark)

15:05–15:35 Why not combine earlier? J Seufert (Germany)

15:35–16:00 What can we expect for future management of diabetes? M Davies (UK)

16:00–16:25 How should we make the right treatment choices for our patients? Panel discussion led by C Mathieu (Belgium), J Vora (UK)

16:25–16:30 Wrap up and close C Mathieu (Belgium), J Vora (UK)

Professor Chantal MathieuUniversity of Leuven, Leuven, Belgium (Co-chair)

Professor Jiten VoraHead of External Scientific Affairs, AstraZeneca, and Professor of Endocrinology, University of Liverpool, Liverpool, UK (Co-chair)

May 2015 – ATLAS ID: 762.302,011 Expiry date: 18 September 2015

786206046-001_A4 layout_v5.indd 1 22/05/2015 15:01

3

WELCOME ADDRESS

Dear Guests,

It will be a great honour and pleasure to welcome you to the 51st EASD Annual Meeting from 14 – 18 September 2015 in Stockholm, Sweden.

For many years, an integral part of the EASD Congress has been the symposia on the occasion of our Annual Meeting which have provided state-of-the-art information on developments in diabetes care and research.These symposia offer a range of valuable information and knowledge on clinical and basic research in the field of diabetes, new and upcoming treatments and major developments in the field of diabetes and its complications.

They attract opinion leaders, academic researchers, physicians and other health care professionals and offer an excellent platform for discussion and the opportunity to learn about new research as well as the latest news and updates in the world of diabetes research and care.

Beginning on September 14 with the industry symposia, an international audience of academics, researchers and physicians from over 100 countries will descend on the Stockholmsmässan in Stockholm.

For the first time in the history of the EASD Congress, I have the pleasure to invite you to attend the industry mini symposia, which take place in the afternoon of 14 September, and the industry evening symposia, which take place directly after the EASD Scientific Programme on 17 September.

These sessions provide an outstanding forum for interaction, communication, education and collaboration and are an excellent introduction to the official EASD Scientific Programme which will begin on September 15.

On behalf of EASD and the Local Organising committee, I encourage you to actively take part in the symposia on the occasion of the Annual Meeting of the European Association for the Study of Diabetes during what promises to be an outstanding 51st EASD Annual Meeting.

I look forward to welcoming you to Stockholm.

Prof. Andrew J.M. BoultonPresident, EASD

4

CONTENTSChEDuLE ................................................................................................................................ 5hALL OvERviEW ...................................................................................................................... 6PROgRAMME Of iNDuSTRy SyMPOSiA ............................................................................7

Sanofi DiabetesDifferent patients, different needs: towards an integrated care approach in diabetes care ..........................................8Novo NordiskEvolving perspectives in treating diabetes and obesity ...............................................................................................10AstraZenecaIndividualised patient care in Type 2 diabetes: translating science to practice ...........................................................12Boehringer Ingelheim & Eli Lilly and Company Getting to the heart of Type 2 Diabetes .......................................................................................................................13Novartis PharmaceuticalsThe future of diabetes: opportunities and challenges ..................................................................................................14DexComDexcom Continuous Glucose Monitoring in 2015 – Clinical Practice, Technology Innovations and Market Access .........16Pfizer Translational Pursuits ................................................................................................................................................... 17Zydus CadilaSAROGLITAZAR – A breakthrough discovery in the management of metabolic disorders .........................................18Merck Sharp & DohmeLessons Learned from the TECOS CV Safety Trial and the Evolving Role of DPP-4 Inhibitors in the Treatment of Patients with Type 2 Diabetes .......................................................................................................19AmgenDiabetic dyslipidemia, cardiovascular disease and PCSK9 inhibition with evolocumab: 4 key questions ................20Becton Dickinson & Company Inc.Optimizing Insulin Pump Therapy: Infusion Set Failures and Silent Occlusions .........................................................22TakedaShould type 2 diabetes (T2D) management be more of a priority in post-acute coronary syndrome (ACS) patients? .... 24Roche Diabetes CareHow much can technology support Personalized Diabetes Management .................................................................26Medscape Education supported by an independent educational grant from JanssenShould SGLT2 Inhibitors Be An Integral Part of a Personalized Treatment Plan for Type 2 Diabetes? ......................28AbbottOne year with flash glucose monitoring – Perspectives from different stakeholders in diabetes care. What’s next? .......29

PROgRAMME Of iNDuSTRy MiNi SyMPOSiA ................................................................30LG Life SciencesWhat is the Optimized treatment for T2DM patients? ................................................................................................30AegerionThe Metabolic Chaos of Lipodystrophy – Finding the Order Within ..........................................................................32Eli Lilly and CompanyChallenges in Comprehensive Lipid Management .....................................................................................................33

PROgRAMME Of iNDuSTRy EvENiNg SyMPOSiA .......................................................35Novo NordiskGLP-1 receptor agonists: liraglutide 3.0 mg in weight management .........................................................................35Boehringer Ingelheim & Eli Lilly and CompanyEMPA-REG OUTCOME®: Implications for management of patients with Type 2 Diabetes ........................................36Merck Sharp & DohmeThe TECOS CV Safety Trial and the Lessons Learned for Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease .......................................................................................................................................38Eli Lilly and CompanyThe Patient in Mind: new perspectives on injectable therapy for type 2 diabetes .....................................................39

BADgES DuRiNg SyMPOSiA DAyS ...................................................................................41 iMPRiNT ...................................................................................................................................42

5

SChEDuLEMonday, 14 September 2015 Industry Symposia

09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00

Keen Hall Sanofi DiabetesPage 8

Hellerström Hall Novo NordiskPage 10

Heding Hall AstraZenecaPage 12

Peltonen-Palotie Hall

Boehringer Ingelheim & Eli Lilly and CompanyPage 13

Jacobsohn Hall NovartisPage 14

Meyer-Schwickerath Hall

DexCom Page 16

AmgenPage 20

Rahbar Hall A Zydus CadilaPage 18

Doniach Hall Merck Sharp & DohmePage 19

Rahbar Hall B PfizerPage 17

Becton Dickinson & Company, Inc.Page 22

Kimmelstiel Hall TakedaPage 24

Bouchardat Hall Roche Diabetes CarePage 26

Loubatière Hall Medscape EducationPage 28

Sterne Hall AbbottPage 29

Thursday, 17 September 2015 Industry Evening Symposia19:00 20:00 21:00

Loubatière Hall Novo NordiskPage 35

Meyer-Schwickerath Hall

Boehringer Ingelheim & Eli Lilly and Company Page 36

Kimmelstiel Hall Merck Sharp & DohmePage 38

Elite Hotel Marina Tower

Eli Lilly and CompanyPage 39

Monday, 14 September 2015 Industry Mini Symposia17:00 – 18:00

Schmidt Hall LG Life SciencesPage 30

Hodgkin Hall AegerionPage 32

Pirart Hall Eli Lilly and CompanyPage 33

Sanger Hall AstraZeneca

6

hALL OvERviEW

Sanger Hall

Schmidt Hall

Kimmelstiel Hall

Bouchardat Hall

HodgkinHall

Pirart Hall

Sterne Hall

LoubatièreHall

RahbarHall A

Peltonen-PalotieHall

Heding Hall

DoniachHall

JacobsohnHall

HellerströmHall

POSTER

EXHIBITION

Ass

oci

atio

ns’ V

illag

e

KeenHall

to First Floor

RegistrationArea

MAINENTRANCE

RahbarHall B

Meyer-Schwickerath

Hall

EXITONLY

Scientific Halls Symposia Halls Exhibition

RegistrationArea

Älvsjö Station

Programme of Industry Symposia

DIfferent PatIentS, DIfferent neeDS: towarDS an IntegrateD care aPProach

In DIabeteS care

Keen Hall09:00 – 09:10 Welcome and introduction Richard Bergenstal (USA), Lars Rydén (Sweden)

09:10 – 09:20 Different patients, different needs, different approaches Athena Philis-Tsimikas (USA)

OPTIMISING AND ADVANCING BASAL INSULIN09:20 – 09:45 The evolution of basal insulin: New insights Alice Cheng (Canada)

09:45 – 10:10 When it’s time to intensify: What are the options? Robert Henry (USA)

10:10 – 10:30 Interactive audience discussion and patient summary All

10:30 – 10:50 Break

UNDERSTANDING AND MANAGING RISK IN DIABETES CARE10:50 – 11:35 Too high or too low: The risks of hyperglycaemia vs hypoglycaemia Pratik Choudhary (UK), Silvio Inzucchi (USA)

11:35 – 12:00 Getting to the heart of the matter: Understanding cardiovascular risk in diabetes Lars Rydén (Sweden)

12:00 – 12:25 Controlling cholesterol in diabetes Bertrand Cariou (France)

12:25 – 12:45 Interactive audience discussion and patient summary All

12:45 – 13:45 Lunch

EXPANDING THE HORIZONS OF DIABETES CARE13:45 – 13:50 Overview of afternoon session Richard Bergenstal (USA), Lars Rydén (Sweden)

13:50 – 14:00 Different patients, different needs, different approaches Partha Kar (UK)

14:00 – 14:25 Beyond the prescription: Setting, achieving and maintaining target Athena Philis-Tsimikas (USA)

14:25 – 14:50 Beyond pharmacotherapy: Technologies that improve how patients interact with their disease Steve Edelman (USA)

14:50 – 15:15 Beyond the clinic: How can we connect with our patients? Partha Kar (UK)

15:15 – 15:40 Patient integrated care: Comprehensive support for better patient outcomes Richard Bergenstal (USA), Lars Rydén (Sweden)

15:40 – 16:00 Patient summary + closing remarks All

MONDAy, 14 SEPTEMBER 2015 09:00 – 16:00

8

iNDuSTRy SyMPOSiA

Organised by: Sanofi Diabetes

towards an integrated care approach in diabetes

Ima

ge

s sh

ow

n a

re m

od

els

use

d fo

r illu

stra

tive

pu

rpo

ses

on

lySA

GLB

.DIA

.15.

06.0

341

Da

te o

f pre

pa

ratio

n: J

un

e 2

015

JOIN US FOR OUR SYMPOSIUM on the occasion of the 51st EASD Annual Meeting

Keen Hall Stockholm International Fairs & Congress Center Stockholm

MONDAY 14th SEPTEMBER 2015

09.00 –16.00

09.00 –16.00 Optimizing and advancing basal insulin Understanding and managing risk in diabetes care Expanding the horizons of diabetes care

DIFFERENT PATIENTS DIFFERENT NEEDS:

Please visit us at booth B06:31, hall B for further information

103028_EASD 2015_Symposium Ad_v07b_PORTRAIT.indd 1 19/06/2015 17:11

evolvIng PerSPectIveS IntreatIng DIabeteS anD obeSIty

Hellerström HallMORNING SESSION

09:00 – 09:10 Welcome Host and chair: Bo Ahrén (Sweden)

09:10 – 09:30 Is intensive behavioural therapy enough in obesity management? Michael Lean (UK)

09:30 – 09:45 Mode of action of liraglutide 3.0 mg in weight management Niels Vrang (Denmark)

09.45 – 10:00 Focused weight management strategies – update on clinical practice Nicholas Finer (UK)

10:00 – 10:15 The SCALE phase 3a clinical trial programme – benefits on secondary outcomes Luc Van Gaal (Belgium)

10:15 – 10:45 Coffee

10:45 – 11:05 Personalising the choice of anti-obesity medication (responder analyses) Donna Ryan (USA)

11:05 – 11:20 Mechanisms in cardiovascular effects of GLP-1 Mansoor Husain (Canada)

11:20 – 11:45 Managing diabetes in special populations Melanie Davies (UK)

11:45 – 12:10 Panel discussion

12:10 – 13:10 Lunch


10

iNDuSTRy SyMPOSiA

Organised by: Novo Nordisk

evolvIng PerSPectIveS IntreatIng DIabeteS anD obeSIty

Hellerström HallAFTERNOON SESSION

13:10 – 13:15 Welcome Host: Bo Ahrén (Sweden), Chair: Tina Vilsbøll (Denmark)

13:15 – 13:35 Hypoglycaemia anno 2015: what we have learned Simon Heller (UK)

13:35 – 13:55 What is new in insulin treatment? Tim Heise (Germany) and Christopher Sorli (USA)

13:55 – 14:15 A new choice for diabetes treatment – the dual approach Stephen Gough (UK)

14:15 – 14:35 The clinical potential of the dual approach John Buse (USA)


14:50 – 15:10 Cardiovascular outcomes trials in diabetes – what have we learned and where are we heading? Marc Pfeffer (USA)

15:10 – 15:20 Closure Tina Vilsbøll (Denmark)


11

iNDuSTRy SyMPOSiA


InDIvIDualISeD PatIent care In tyPe 2 DIabeteS: tranSlatIng ScIence to PractIce

Heding Hall10:30 – 11:00 Welcome and introduction Why and when should we treat Type 2 diabetes? Chantal Mathieu (Belgium) / Jiten Vora (UK)

11:00 – 11:30 Treatment decisions for our patients: what are the considerations? Richard Pratley (USA)

11:30 – 11:55 Weight gain in the treatment of Type 2 diabetes: is it inevitable? John Wilding (UK)

11:55 – 12:20 The kidneys in Type 2 diabetes: challenges and opportunities? Mark Cooper (Australia)

12:20 – 12:45 Can we delay escalation to insulin therapy? Tina Vilsbøll (Denmark)

12:45 – 13:00 What steps should we take to stop progression of poor glucose control? Chantal Mathieu (Belgium) / Jiten Vora (UK)

13:00 – 14:00 Lunch 14:00 – 14:10 Welcome back Chantal Mathieu (Belgium) / Jiten Vora (UK)

14:10 – 14:40 Safety of novel therapies in Type 2 diabetes: what’s the latest? Juris Meier (Germany)

14:40 – 15:05 What is the physiological basis for combining therapies? Jens Holst (Denmark)

15:05 – 15:35 Why not combine earlier? Jochen Seufert (Germany)

15:35 – 16:00 What can we expect for future management of diabetes? Melanie Davies (UK)

16:00 – 16:25 How should we make the right treatment choices for our patients? Chantal Mathieu (Belgium) / Jiten Vora (UK)

16:25 – 16:30 Wrap up and close Chantal Mathieu (Belgium) / Jiten Vora (UK)


12

iNDuSTRy SyMPOSiA

Organised by: AstraZeneca

13

iNDuSTRy SyMPOSiA

gettIng to the heart of tyPe 2 DIabeteS

Peltonen-Palotie Hall14:00 – 14:05 Welcome Co-chairs: Clifford Bailey (UK) and Nikolaus Marx (Germany)

SESSION 1: THE BROKEN HEARTED – CV RISK AND T2D MANAGEMENT14:05 – 14:25 Tackling CV risk in T2D – time for a change? Kausik Ray (UK)

14:25 – 14:50 New horizons for managing CV risk with anti-hyperglycaemic agents Naveed Sattar (UK)

14:50 – 15:10 The evolving landscape of CV outcome trials in T2D Nikolaus Marx (Germany)

15:10 – 15:25 Q&A Session 1 faculty

SESSION 2: HEALING HEARTACHE – DOES EMOTIONAL ENGAGEMENT WITH BASAL

INSULIN THERAPy IMPROVE OUTCOMES?15:25 – 15:40 How successful is basal insulin therapy in clinical reality? Christophe de Block (Belgium)

15:40 – 15:55 Can the empathy of healthcare professionals increase the success of basal insulin treatment in T2D? Mark Peyrot (USA)

15:55 – 16:00 Q&A Session 2 faculty

16:00 – 16:05 Closing remarks Clifford Bailey (UK)


Organised by: Boehringer Ingelheim & Eli Lilly and Company

14

iNDuSTRy SyMPOSiA

the future of DIabeteS: oPPortunItIeS anD challengeS

Jacobsohn HallChair: Anthony Barnett (UK)

Guest speaker: Sir Michael Hirst (UK)

Faculty members: Kamlesh Khunti (UK)

Mark Cooper (Australia)

Focke Ziemssen (Germany)

Matthias Blüher (Germany)

13:30 – 14:30 PART 1: The vision – opportunities and challenges

14:30 – 14:50 Refreshment break

14:50 – 17:00 PART 2: The reality - opportunities and challenges

14:50 – 15:50 Will optimised diabetes care be accessible in the future?

15:50 – 17:00 Will we be able to prevent the future?


Organised by: Novartis Pharmaceuticals

Item code: GLCM/GAL/0033 | GLRET/LUC/0373 | SE1505339866 Date of preparation: May 2015. ©2015 Novartis Pharma AG, CH-4002 Basel, Switzerland

This symposium may include discussion on products and/or indications still under investigation. Physicians may only prescribe products in accordance with their prescribing information. Prescribing information differs from country to country. Please refer to your local prescribing information.

THE FUTURE OF DIABETES

A Novartis-sponsored symposium on the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes

Opportunities & challenges

14 September 2015 13:30–17:00 Jacobsohn Hall, Stockholmsmässan, Stockholm, Sweden

13:30–14:30 PART 1: The vision - opportunities and challenges

14:30–14:50 Refreshment break

14:50–17:00 PART 2: The reality - opportunities and challenges

14:50–15:50 Will optimised diabetes care be accessible in the future?

15:50–17:00 Will we be able to prevent the future?

Anthony Barnett (Chair), UKSir Michael Hirst, UKKamlesh Khunti, UKMark Cooper, AustraliaFocke Ziemssen, Germany Matthias Blüher, Germany

AgendaFaculty













AgendaFaculty













AgendaFaculty













AgendaFaculty

Dexcom contInuouS glucoSe monItorIng In 2015 – clInIcal PractIce, technology

InnovatIonS anD market acceSS

Meyer-Schwickerath HallModerator: Peter Adolfsson (Sweden)

10:00 – 10:50 Using Dexcom CGM in Clinical Practice – Education and Medical Management Peter Adolfsson (Sweden)

10:50 – 11:40 Current and Future Dexcom CGM Technology Innovations Jake Leach (USA)

11:40 – 12:30 Continuous Glucose Monitoring – Cost Modeling and Reimbursement Claudia Graham (USA)


16

iNDuSTRy SyMPOSiA

Organised by: DexCom

tranSlatIonal PurSuItS

Rahbar Hall BHost Prof. Morrie Birnbaum (USA)

CSO, Pfizer CVMED

Chair Dr Julia Brosnan (USA)

10:00 – 10:10 Welcome and Opening Julia Brosnan (USA)

10:10 – 10:40 A fine-tuned classification of diabetes – steps towards individualized medicine Leif Groop (Sweden)

10:40 – 11:20 Rare and Frequent DNA Variation and Precision Diabetic Medicine Philippe Froguel (France)

11:20 – 11:50 Building a target hypothesis: genetic associations are only the start Daniel Ziemek (Germany)

11:50 – 12:30 Diamonds in the Dirt – using human genetics to Define Biology and Guide translation in type 2 Diabetes Mark McCarthy (UK)


17

iNDuSTRy SyMPOSiA

Organised by: Pfizer

18

iNDuSTRy SyMPOSiA

SaroglItaZar – a breakthrough DIScovery In the management of metabolIc DISorDerS

Rahbar Hall AChairs Banshi Saboo (India), S. K. Sharma (India)

14:30 – 14:50 Diabetic dyslipidemia & its management: Review of current therapeutic options Charles Burant (USA)

14:50 – 15:10 PPAR agonism: Role in metabolic disorders Walter Wahli (Switzerland)

15:10 – 15:30 Saroglitazar: Concept to clinic Shashank R. Joshi (India)

15:30 – 15:50 Saroglitazar: An endocrinologist’s perspective Anil Bhansali (India)

15:50 – 16:10 Saroglitazar: A cardiologist’s perspective Saumitra Ray (India)

16:10 – 16:30 Saroglitazar: NASH perspective Sujoy Ghosh (India)



Organised by: Zydus Cadila

19

iNDuSTRy SyMPOSiA

leSSonS learneD from the tecoS cv Safety trIal anD the evolvIng role of DPP-4 InhIbItorS In the

treatment of PatIentS wIth tyPe 2 DIabeteS

Doniach Hall14:30 – 14:35 Chair Welcome and Opening Remarks Co-Chairs: Rury Holman (UK), Michel Komajda (France)

14:35 – 15:05 Are we Treating Patients Based on the Evidence? Previous Cardiovascular Trials: Michel Komajda (France)

DPP-4 CV Safety Trials: Michael Nauck, (Germany)

15:05 – 15:20 Audience Vote and Discussion led by Chairmen

15:20 – 15:40 DPP-4 Inhibitors: What is the Latest Science? Carolyn Deacon (Denmark)

15:40 – 15:50 Q&A

15:50 – 16:20 Lessons Learned from the TECOS CV Safety Trial: The Role of Sitagliptin in the Treatment of Cardiovascular Patients with Type 2 Diabetes Rury Holman (UK)

16:20 – 16:30 Q&A

16:30 – 16:55 Specialty Dialogue: Treatment of Patients with Type 2 Diabetes from an Endocrinology, Nephrology and Cardiology View Faculty

16:55 – 17:00 Final Comments and Summary Chairmen: Rury Holman (UK), Michel Komajda (France)


Organised by: Merck Sharp & Dohme

20

iNDuSTRy SyMPOSiA

DIabetIc DySlIPIDemIa, carDIovaScular DISeaSe anD PcSk9 InhIbItIon wIth

evolocumab: 4 key queStIonS

Meyer-Schwickerath Hall14:30 – 14:35 Welcome and introduction Marja-Riitta Taskinen (Finland)

Handrean Soran (UK)

14:35 – 15:05 Targeting dyslipidemia in diabetes, is it important? Neil Poulter (UK)

15:05 – 15:35 Patients who cannot tolerate a maximum dose of statins, what should we do? Ulrich Laufs (Germany)

15:35 – 16:05 What is PCSK9 and why should you be interested in it? John Chapman (France)

16:05 – 16:45 Debate: Is LDL-C reduction more important than glucose lowering in diabetes? For: Kausik Ray (UK)

Against: Naveed Sattar (UK)

16:45 – 17:00 Panel questions and closing remarks Marja-Riitta Taskinen (Finland)

Handrean Soran (UK)


Organised by: Amgen

21

iNDuSTRy SyMPOSiA

Amgen (Europe) GmbH Dammstrasse 23

CH-6300 Zug Switzerland

© 2015 Amgen Inc. All rights reserved. EUHQ-NP-145-0615-107185 June 2015

Programme

Welcome and introduction Marja-Riitta Taskinen, Finland and Handrean Soran, UK

Targeting dyslipidemia in diabetes, is it important? Neil Poulter, UK

Patients who cannot tolerate a maximum dose of statins, what should we do now? Ulrich Laufs, Germany

What is PCSK9 and why should you be interested in it? John Chapman, France

Debate: Is LDL-C reduction more important than glucose lowering in diabetes? For: Kausik Ray, UK Against: Naveed Sattar, UK

Panel questions and closing remarks Marja-Riitta Taskinen, Finland and Handrean Soran, UK

Diabetic dyslipidemia, cardiovascular disease and PCSK9 inhibition with evolocumab: 4 key questions

refreshments will be available prior to the symposium

monday 14 September 2015, 14.30–17.00Meyer-Schwickerath Hall, Stockholmsmässan, Stockholm, Sweden

Symposium on the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes

22

iNDuSTRy SyMPOSiA

oPtImIZIng InSulIn PumP theraPy: InfuSIon Set faIlureS anD SIlent occluSIonS

Rahbar Hall B14:00 – 14:30 Registration

14:30 – 14:35 Welcome, Faculty Disclosures and Program Objectives

14:35 – 14:40 Pre-test Using Audience Response System

14:40 – 15:00 Current Perspectives on Insulin Dynamics in the Subcutaneous Space Prof. Lutz Heinemann (Germany)

15:00 – 15:30 The Science of Infusion Sets: Gaps in Clinical Evidence Dr. Bruce A. Buckingham (USA)

15:30 – 15:50 Paediatric Clinical Case Prof. Thomas Danne (Germany)

15:50 – 16:10 New Insulin Infusion Set Technology Dr. Laurence J. Hirsch (USA)

16:10 – 16:20 Toward the Artificial Pancreas: Clinical Perspectives on Opportunities and Gaps Prof. J. Hans De Vries (The Netherlands)

16:20 – 16:30 New Research: What the Future Holds Dr. Aaron Kowalski (USA)

16:30 – 16:45 Demonstrations

16:45 – 16:50 Questions & Answers

16:50 – 16:55 Post-test Using Audience Response System

16:55 – 17:00 Closing Remarks


Organised by: Becton Dickinson & Company Inc.

23

iNDuSTRy SyMPOSiA

Provided by Athena Education Group, LLC

Supported by Becton, Dickinson and Company

OPTIMIZING INSULIN PUMP THERAPY Infusion Set Failures and Silent Occlusions

Register atwww.bdsympo2015.com

A symposium on the occasion of the 51st EASD Annual Meeting

MONDAY, 14 SEPTEMBER 201514:30–17:00Rahbar Hall BStockholmsmässan Stockholm, Sweden

EDUCATIONAL OBJECTIVESAfter participating in the symposium, the learner will be able to:

• Recognize knowledge gaps and technical issues associated with the use of insulin infusion sets, including flow interruptions with infusion sets

• Identify strategies to improve patient and healthcare professional knowledge gaps around insulin infusion sets

• Review potential benefits of new infusion set technology in clinical care

AGENDA

For more information, please email [email protected]

14:00–14:30 Registration and Light Refreshments

14:30–14:35 Welcome, Faculty Disclosures, and Program Objectives

14:35–14:40 Pre-test Using Audience Response System

14:40–15:00 Current Perspectives on Insulin Dynamics in the Subcutaneous Space Lutz Heinemann, PhD

15:00–15:30 The Science of Infusion Sets: Gaps in Clinical Evidence Bruce A. Buckingham, MD

15:30–15:50 Paediatric Clinical Case Thomas Danne, MD

15:50–16:10 New Insulin Infusion Set Technology Laurence J. Hirsch, MD

16:10–16:20 Toward the Artificial Pancreas: Clinical Perspectives on Opportunities and Gaps J. Hans De Vries, MD, PhD

16:20–16:30 New Research: What the Future Holds Aaron Kowalski, PhD

16:30–16:45 Demonstrations

16:45–16:50 Questions & Answers

16:50–16:55 Post-test Using Audience Response System

16:55–17:00Closing Remarks

BD, BD logo and all other trademarks are property of Becton, Dickinson and Company © 2015 BD

FACULTYBruce A. Buckingham, MD (Co-Chair)Professor of Pediatrics (Endocrinology)Lucile Salter Packard Children’s HospitalLos Gatos, California, USA

J. Hans De Vries, MD, PhD (Co-Chair)Lecturer & Consultant EndocrinologistDepartment of EndocrinologyAcademic Medical CentreAmsterdam, The Netherlands

Thomas Danne, MDDiabetes Centre for Children and AdolescentsJanusz-Korczak-Allee 12Hannover, Germany

Lutz Heinemann, PhD Science & Co

Düsseldorf, Germany

Laurence J. Hirsch, MDVP Worldwide Medical Affairs Diabetes CareBecton, Dickinson and CompanyFranklin Lakes, New Jersey, USA

Aaron Kowalski, PhDChief Mission Officer and VP, ResearchJDRFNew York, New York, USA

24

iNDuSTRy SyMPOSiA

ShoulD tyPe 2 DIabeteS (t2D) management be more of a PrIorIty In PoSt-acute coronary Syn-

Drome (acS) PatIentS?

Kimmelstiel HallChair: Ele Ferrannini (Italy)

14:30 – 14:45 Welcome Ele Ferrannini (Italy)

14:45 – 15:10 The ACS patient journey: where does T2D fit in? Jean-Claude Tardif (Canada)

15:10 – 15:50 Perspectives of diabetes and cardiovascular-risk management in post-ACS T2D patients · Cardiologist’s perspective Stephen Nicholls (Australia)

· Diabetologist’s perspective Jørgen Rungby (Denmark)

15:50 – 16:30 What do we know about the safety of oral anti-diabetics in post-ACS T2D patients? Exploring evidence from recent outcomes studies Faiez Zannad (France)

16:30 – 16:55 Debating the optimal management of post-ACS T2D patients All speakers, facilitated by Ele Ferrannini

16:55 – 17:00 Conclusions and close Ele Ferrannini (Italy)


Organised by: Takeda

25

iNDuSTRy SyMPOSiA

Takeda-sponsored symposium Kimmelstiel Hall,

Monday 14 September 2015; 14:30–17:00

On the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes, Stockholm, Sweden,

14 – 18 September 2015

Should type 2 diabetes (T2D) management be more of a priority in post-acute coronary

syndrome (ACS) patients?

Putting the spotlight on T2D management in post-ACS patients

Chair: Professor Ele Ferrannini

Job code: GLO/ALO/2015-00055Date of preparation: May 2015

26

iNDuSTRy SyMPOSiA

how much can technology SuPPort PerSonalIZeD DIabeteS management?

Bouchardat HallChairs: Rudy Bilous (UK) + Rolf Hinzmann (Germany)

14:30 – 14:40 Introduction

14:40 – 15:05 Surfing safely in the diabetes app tsunami Ashleigh Walker (Canada)

15:05 – 15:30 The benefits mobile health solutions like the Accu-Chek® Connect system can bring to Personalized Diabetes Management Fabio Broglio (Italy)

15:30 – 15:55 Personalized Diabetes Management today and tomorrow – options for better diabetes therapy Matthias Axel Schweitzer (Germany)

15:55 – 16:20 First results of the Accu-Chek® Insight EU Study Julia Mader (Austria)

16:20 – 16:45 CGM – Developments, indications, performance Peter Adolfsson (Sweden)

16:45 – 17:00 Discussion and closing


Organised by: Roche Diabetes Care

27

iNDuSTRy SyMPOSiA

New Accu-Chek® solutions for you

The Accu-Chek® Connect diabetesmanagement system

Better connectedfor better decisions

The Accu-Chek® Insight diabetestherapy system

Designed with your patients’ lives in mind

Visit us in Hall B at stand 10.31 and fi nd out more

For more information about Accu-Chek, visit www.accu-chek.com

ACCU-CHEK, ACCU-CHEK AVIVA CONNECT, ACCU-CHEK AVIVA INSIGHT, ACCU-CHEK CONNECT and ACCU-CHEK INSIGHT are trademarks of Roche. © 2015 Roche Diabetes Care

Experience what’s possible.

www.accu-chek.comRoche Diabetes Care GmbHSandhofer Str. 116D-68305 Mannheim

N5001_EASD_ISPAD_Ad_A4_RZ.indd 1 26.06.15 10:41

28

iNDuSTRy SyMPOSiA

ShoulD Sglt2 InhIbItorS be an Integral Part of a PerSonalIZeD treatment Plan

for tyPe 2 DIabeteS?

Loubatière Hall14:30 – 14:40 Introduction and Welcome Guntram Schernthaner (Austria)

14:40 – 15:00 Updates on the Clinical and Physiologic Effects of SGLT2 Inhibition: What Have We Learned? Guntram Schernthaner (Austria)

15:00 – 15:30 Expanding Treatment Options for Glycemic Reduction in Patients with T2DM: Role of SGLT2 Inhibitors Francisco Javier Ampudia-Blasco (Spain)

15:30 – 15:55 Non-glycemic Effects of SGLT2 Inhibitors: How Novel Antihyperglycemic Therapy May Improve Patient Outcomes Ronan Roussel (France)

15:55 – 16:40 Putting It All Together: Practical Considerations for Using SGLT2 Inhibitors in the Management of Patients with T2DM John P. H. Wilding (UK)

16:40 – 16:58 Q&A Session Faculty Panel

16:58 – 17:00 Conclusions John P. H. Wilding (UK)


Organised by: Medscape Education supported by an independent educational grant from Janssen

29

Sterne Hall Chair: Professor Jan Bolinder (Sweden)

14:35 – 15:05 Clinical experience with FreeStyle Libre Stig Attvall (Sweden)

15:05– 15:35 Ambulatory Glucose Profile (AGP) through the diabetes care continuum Dr. med. Oliver Schubert (Germany)

15:35 – 16:05 The Impact of AGP and FreeStyle Libre on the Patient – Clinician Dialogue in T1 Diabetes Stephen Dixon and Dr. Pratik Choudhary (UK)

16:05 – 16:35 The Impact of AGP and FreeStyle Libre on the Patient – Clinician Dialogue in T2 Diabetes Dr. med. Oliver Schubert (Germany)

16:40 – 17:00 Panel Discussion Professor Jan Bolinder and all Presenters

one year wIth flaSh glucoSe monItorIng – PerSPectIveS from DIfferent StakeholDerS

In DIabeteS care. what’S next?


Organised by: Abbott

iNDuSTRy SyMPOSiA

what IS the oPtImIZeD treatment for t2Dm PatIentS?

Schmidt Hall17:00 – 17:10 Welcome Address of Chairman Prof. Moon-Kyu Lee (Korea)

17:10 – 17:30 Gemigliptin: The Optimized DPP-4 inhibitor for T2DM Patients Prof. Soo Lim (Korea)

17:30 – 17:50 The Optimal Management in T2DM Patients with Renal Impairment Prof. Eun-Jung Rhee (Korea)

17:50 – 18:00 Q&A and Closing


30

Organised by: LG Life Sciences

iNDuSTRy MiNi SyMPOSiA

aDvancIng DIabeteS treatment anD future Per-SPectIveS

xxxxxx

Bernard Hall08:30 – 09:00 Pre-symposium breakfast

Chair: Jiten Vora (UK)Host: Ramon Gomis (ES)

09:00 – 09:10 Welcome to Novo Nordisk symposium at EASD Ramon Gomis (ES)

09:10 – 09:20 Introduction and update on basal insulin therapy Jiten Vora (UK)

09:20 – 09:40 Opportunities from designer proteins Peter Kurtzhals (DK)

09:40 – 09:55 Clinical profiles of new long-acting insulins and insulin combination products Thomas Pieber (AT)

09:55 – 10:10 Improving efficacy without compromising the risk of hypoglycaemia Athena Philis-Tsimikas (US)

10:10 – 10.25 Flexibility in dose timing matching patient needs Luigi Meneghini (US)

10:25 – 10:55 Coffee break

10:55 – 11:10 Synergies of complementary drugs John Buse (US)



31

iNDuSTRy SyMPOSiA


32


the metabolIc chaoS of lIPoDyStroPhy – fInDIng the orDer wIthIn

Hodgkin HallKeynote speaker: Prof. Abhimanyu Garg (USA)

17:00 – 17:05 Welcome and introduction

17:05 – 17:45 Keynote speech Prof. Abhimanyu Garg (USA)

17:45 – 18:00 Questions and Answers


Organised by: Aegerion

33


challengeS In comPrehenSIve lIPID management

Pirart Hall

17:00 – 17:05 Welcome & Objectives

17:05 – 17:20 Cardiovascular Risk in Diabetes Patients: Just About Lipid Modification? Peter J. Grant (United Kingdom)

17:20 – 17:35 Dyslipidemia and Atherogenicity in T2DM: Looking Beyond the Obvious Alberto Zambon (Italy)

17:35 – 17:50 What is the Role of CETP in Lipid Metabolism? José María Mostaza Prieto (Spain)

17:50 – 18:00 Expert Panel


Organised by: Eli Lilly and Company

34


34

INDUSTRY PRogRammeSaVe THe DaTe

12 – 16 September 2016munich

on the occasion of the

52nd annual meeting of the european association

for the Study of Diabetes


www.easd-industry.com

12 September 2016

13 – 15 September 2016

15 September 2015

Industry Symposia & Industry mini Symposia

Industry exhibition

Industry evening Symposia

35

glP-1 recePtor agonIStS: lIraglutIDe 3.0 mg In weIght management

Loubatière Hall19:00 – 19:05 Welcome and introduction Joanna Uddén Hemmingsson (Sweden)

19:05 – 19:20 The role of GLP-1 in weight management: targeting central nervous system appetite regulation Darleen Sandoval (USA)

19:20 – 19:35 Optimising the dose for weight management: phase 2 results Nick Finer (UK)

19:35 – 20:00 SCALE Obesity and Prediabetes & SCALE Maintenance: key results Carel Le Roux (Ireland)

20:00 – 20:15 SCALE Diabetes: key results Tina Vilsbøll (Denmark)

20:15 – 20:30 Panel discussion All faculty

THURSDAy, 17 SEPTEMBER 2015 19:00 – 20:30


iNDuSTRy EvENiNg SyMPOSiA

emPa-reg outcome®: ImPlIcatIonS for management of PatIentS

wIth tyPe 2 DIabeteS

Meyer-Schwickerath Hall19:00 – 19:05 Welcome and introduction Lars Rydén (Sweden)

19:05 – 19:40 Exploring the results of EMPA-REG OUTCOME® Bernard Zinman (Canada)

19:40 – 20:20 Treatment of Type 2 Diabetes and cardiovascular risk in the context of EMPA-REG OUTCOME® Lars Rydén (Sweden)

Sanjay Kaul (USA)

Lawrence Leiter (Canada)

Naveed Sattar (UK)

20:20 – 20:30 Conclusion, summary and close Lars Rydén (Sweden)


36


Organised by: Boehringer Ingelheim & Eli Lilly and Company

37

THIS ADVERTISEMENT PREPARED BY AREA23 Sig Date Time Time Spent Spell Check

Mac Op

QC

Editing

Copywriting

Art Director

Art Buying

Account

Traffic

Production

DQC

Client: BIProduct: Jardiance Global +EmpaMetJob#: 10361144Colors: 4C Sizes: Bleed: 216mm x 303mm

Sm Trim: 210mm x 297mmLive: 190mm x 277mmgutter: .375”

Publications:

A Size

It’s a pill with benefi ts I could appreciate?

TO

THAT

DOCTORSPEAKS

It’s a pill with benefi ts I could appreciate?Find out more at Booths

B10:21 and B10:20

Now those are benefi ts your patients could appreciate.

Issued June, 2015

Jardiance (empaglifl ozin) 10 mg, 25 mg fi lm-coated tablets, prescription only SGLT2 inhibitor.

Therapeutic indications:Jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as monotherapy: when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; add-on combination therapy: in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

Contraindications:Hypersensitivity to the active substance or any of the excipients.

Special warnings and precautions for use: Should not be used in patients with type 1 diabetes or diabetic ketoacidosis; patients with ESRD or in patients with dialysis; should not be initiated in patients with eGFR below 60 mL/min/1.73 m2; caution should be exercised in patients with a risk for volume depletion, such as patients aged 75 years or older, those on anti-hypertensive therapy with a

history of hypotension, with well known cardiovascular disease. In patients tolerating empaglifl ozin whose eGFR falls persistently below 60 mL/min/1.73 m2

or CrCl below 60 mL/min, the dose of empaglifl ozin should be adjusted to or maintained at 10 mg once daily. Empaglifl ozin should be discontinued when eGFR is persistently below 45 mL/min/1.73 m2 or CrCl persistently below 45 mL/min.

This drug is subject to additional monitoring. HCPs are asked to report any suspected adverse reactions.

May, 2014

MARKETINGAUTHORISATION HOLDERBoehringer Ingelheim International GmbH, Binger Str. 173, D-55216 Ingelheim am Rhein, Germany.

Further information on warnings and precautions on the use, interactions with other medical products and contraindications can be found in the Summary of Product Characteristics.

This is the prescribing information approved for use in Sweden. Please refer to your local prescribing information as this information may vary from country to country.

Synjardy (empaglifl ozin/metformin hydrochloride), fi lm-coated tablets, prescription only.

Synjardy 5 mg/850 mg. Each tablet contains 5 mg empaglifl ozin and 850 mg metformin hydrochloride.Synjardy 5 mg/1,000 mg. Each tablet contains 5 mg empaglifl ozin and 1,000 mg metformin hydrochloride.Synjardy 12.5 mg/850 mg. Each tablet contains 12.5 mg empaglifl ozin and 850 mg metformin hydrochloride.Synjardy 12.5 mg/1,000 mg. Each tablet contains 12.5 mg empaglifl ozin and 1,000 mg metformin hydrochloride.

SGLT2 inhibitor/Biguanide.Therapeutic indications:Synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximally tolerated dose of metformin alone, in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin, in patients already being treated with the combinationof empaglifl ozin and metformin as separate tablets.

Contraindications:Diabetic ketoacidosis, diabetic pre- coma, renal failure or renal dysfunction (creatinine clearance <60 mL/min), acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock. Acute or chronic disease which may cause tissue hypoxia such as: cardiac or respiratory failure, recent myocardial infarction, shock. Hepatic impairment, acute alcohol intoxication, alcoholism.

This drug is subject to additional monitoring. HCPs are asked to report any suspected adverse reactions.

June, 2015

MARKETING AUTHORISATION HOLDERBoehringer Ingelheim International GmbH, Binger Str. 173, D-55216 Ingelheim am Rhein, Germany.

Further information on warnings and precautions on the use, interactions with other medical products and contraindications can be found in the Summary of Product Characteristics.

This is the prescribing information approved for use in Sweden. Please refer to your local prescribing information as this information may vary from country to country.

• Signifi cant HbA1c reduction with the additional benefi t of weight loss2-5*†

• Effi cacy when added to a range of background treatments, including insulin3-5

• Convenient once-daily oral dosing

SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:

JARDIANCE, an SGLT2 inhibitor for adults with type 2 diabetes, provides1:

• The effi cacy of both empaglifl ozin and metformin in 1 pill6*†

• Flexible dosing options to individualise treatment6

• The convenience of a single-pill combination for your patients

*JARDIANCE and SYNJARDY are not indicated for weight loss. † Weight change was a secondary endpoint in clinical trials.

References: 1. JARDIANCE [summary of product characteristics]. Ingelheim am Rhein, Germany: Boehringer Ingelheim Pharmaceuticals, GmbH; 2014. 2. Roden M et al. Lancet Diabetes Endocrinol. 2013;1:208-219. 3. Häring HU et al. Diabetes Care. 2014;37:1650-1659. 4. Häring HU et al. Diabetes Care. 2013;36:3396–3404. 5. Rosenstock J et al. Poster presented at 49th Annual Meeting of the European Association for the Study of Diabetes; Sept. 23–27, 2013; Barcelona, Spain. 6. SYNJARDY [summary of product characteristics]. Ingelheim am Rhein, Germany: Boehringer Ingelheim Pharmaceuticals, GmbH; 2015.

To learn more about JARDIANCE and SYNJARDY,please contact your local representative.

Please see full Prescribing Information for additional information.

10361144_Jard+EmpaMet_EASD_JournalAd_FR.indd 2 6/11/15 6:24 PM

38


the tecoS cv Safety trIal anD the leSSonS learneD for treatment of PatIentS wIth

tyPe 2 DIabeteS anD carDIovaScular DISeaSe

Kimmelstiel HallCo-Chairs: Niko Marx (Germany)

Juris Meier (Germany)

19:00 – 19:05 Welcome Niko Marx (Germany) and Juris Meier (Germany)

19:05 – 19:20 Continuing our Understanding of the Role DPP-4 Inhibitors Play in the Cardiovascular Patient with Type 2 Diabetes Richard Gilbert (Canada)

19:20 – 19:30 Q and A

19:30 – 19:55 TECOS CV SAFETy TRIAL: New Data from the CV Safety Trial for Sitagliptin Rury Holman (UK)

19:55 – 20:05 Q and A

20:05 – 20:25 Faculty Specialty Dialogue: Lessons Learned for the Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease All faculty

20:25 – 20:30 Closing Comments Niko Marx (Germany) and Juris Meier (Germany)


Organised by: Merck Sharp & Dohme

39


the PatIent In mInD: new PerSPectIveS on Injectable theraPy

for tyPe 2 DIabeteS

Elite Hotel Marina TowerChair: Michael Nauck (Germany)

19:00 – 19:05 Introduction/Opening Michael Nauck (Germany)

19:05 – 19:25 Understanding the T2DM patient transition to injectable therapy Melanie Davies (UK)

19:25 – 19:45 What drives treatment persistence and preference in T2DM? Francesco Giorgino (Italy)

19:45 – 20:10 Can weekly GLP-1 RAs influence the current perspective of injectable therapies? A commentary on the latest data Michael Nauck (Germany)

20:10 – 20:30 Panel discussion + Wrap up Michael Nauck (Germany)

Please note this meeting is by registration only.

Please contact Lilly staff for further details.


Organised by: Eli Lilly and Company


fOR fuRThER DETAiLS, PLEASE CONTACTINTERPLAN

Congress, Meeting & Event Management AG

Landsberger Str. 155

80687 Munich, Germany

Phone: +49 89 - 54 82 34-9055

Email: [email protected]

fiND yOuR PERfECT PLACE TO STAy iN MuNiCh!

The hotel capacities are limited and it is recommended to arrange your booking early.

http://hotels2016.easd-industry.com/

Username hotels2016Password Munich*16

41

BADgES DuRiNg SyMPOSiA DAyS

Due to safety reasons, the entrance to the conference site during the industry symposia on the occasion of the 51st EASD Annual Meeting will be strictly controlled.

This means that each regular attendee of the symposia day has to be identified as authorised by wearing a badge.

Our security staff will accept the following types of badges or name labels only:

• Regular delegate badge

• Regular exhibitor badge

• Special name tags, provided by the company itself, showing the status of the person wearing: “Invited by …, Guest of …, Technician of…“

Type of DelegateType of Badge

Access to Industry

Symposia 14.09.15

Access to the Scientific Sessions

15.– 18.09.15

Access to Industry Evening

Symposia 17.09.15

Access to the Industry

Exhibition 15.– 17.09.15

Speaker / Delegate registered for the Scientific Programme of the EASD Annual Meeting

Congress Badge ✔ ✔ ✔ ✔

Speaker / Delegate registered as an exhibitor for the Industry Exhibition of the EASD Annual Meeting

Exhibitor Badge ✔ ✘ ✔ ✔

Company Speaker / Delegate not registered for the EASD Annual Meeting

Own Company created Badge

✔ ✘ ✘ ✘

42

iMPRiNT

c/o INTERPLAN AGLandsberger Strasse 15580687 MunichGermany

Phone: +49 (0) 89 54 82 34-67Fax: +49 (0) 89 54 82 34-45Email: [email protected]: www.interplan.de

Picture on page 7: © Stockholmsmässan, Karl GaborEach company is responsible for the content of their symposium.Status: July 2015. All subjects to change.


ABASAGLAR 100 units/mL solution for injection (insulin glargine)Cartridge, pre-filled pen (KwikPen™)

This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.

ATC code: A10AE04Drugs used in diabetes. Insulins and analogues for injection, long-acting.

Indications: Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.Contraindications: Hypersensitivity to the active substance or to any of the excipients.Warnings: ABASAGLAR is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously is recommended in such cases. In case of insufficient glucose control or a tendency to hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, long acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose. Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.Date of revision of the text: 17 February 2015 For further information and prices see www.fass.seRx, not FThis text is based on the Swedish prescribing information. Please contact your local Lilly representative for information relevant to your country.

Eli Lilly Sweden AB, Box 721, 169 27 Solna. 08-737 88 00. www.lilly.se.

Date of last SmPC update: 2015-04-16

LET’S TALK ABOUT helping your patients feel better about starting basal insulin.Introducing ABASAGLAR—a once-daily insulin glargine with clinical benefits you may

find familiar and an initiation experience your patients may find appealing.

Visit Lilly booth B10:20 and BI booth B10:21 to learn more.

SEDBT01535 02-JUN-2015

THIS ADVERTISEMENT PREPARED BY AREA23 Sig Date Time Time Spent Spell Check

Mac Op

QC

Editing

Copywriting

Art Director

Art Buying

Account

Traffic

Production

DQC

Client: BI Product: Basaglar Job#: 10347992Colors: 4C Sizes: Bleed: 213mm x 300mm

Trim: 210mm x 297mm Live: 209mm x 296mm gutter: N/A

Publications:

A Size

10347992_EASD_Journal_Ad_FR.indd 1 6/4/15 11:45 AM

Join us at this state-of-the-art symposium and be one of the first to discuss the results of the EMPA-REG OUTCOME™ trial with leading experts

EMPA-REG O

UTCOME™:

Impl

icatio

ns fo

r man

agem

ent

of pa

tient

s with

Type

2 Diab

etes

17 S

epte

mbe

r 201

5, 19

:00–

20:3

0; C

hair:

Lar

s Ryd

én

Mey

er-S

chwick

erat

h Hal

l, Sto

ckho

lm In

tern

ation

al Fa

irs an

d Con

gres

s Cen

tre, S

weden

Lars R

ydén

(Swed

en)

Lars R

ydén

(Swed

en)

Lars R

ydén

(Swed

en)

Sanja

y Kau

l (USA

)Law

rence

Lei

ter (

Canad

a)

Navee

d Sat

tar (

UK)

Bernar

d Zinm

an (C

anad

a)

Bernar

d Zinm

an (C

anad

a)

19:0

0

19:0

5

19:4

0

20:2

0

Wel

com

e and in

troduct

ion

Explo

ring th

e res

ults

of E

MPA-R

EG OUTCOM

E™

Concl

usion, s

umm

ary

and cl

ose

Trea

tmen

t of T

ype 2

Dia

betes

and

card

iova

scula

r risk

in th

e con

text

of E

MPA-R

EG OUTCOM

E™

Panel

disc

ussio

n

Audi

ence

Q&A

D0394 Empa-REG Symposia Ad_A4 S05.indd 1 05/06/2015 08:52

Documents

PROGRAMME of INDUSTRY SYMPOSIA2015.easd-industry.com/files/EASD15/downloads/industry/... · 2015-08-10 · Images shown are models used for illustrative purposes only SAGLB.DIA.15.06.0341